Grâce à un programme de remboursement organisé en collaboration avec le Kankerfonds du Limbourg, InnoSer a récemment fait l’acquisition de deux nouveaux appareils d’imagerie qui permettront d’approfondir les connaissances sur nos plateformes in vitro et in vivo destinées à la recherche préclinique en oncologie. Le premier est l’l’ImageXpress Micro 4, unesolution d’imagerie de cellules vivantes à haut contenu, et le second est le système d’imagerie in vivo Lumina III, qui permet l’imagerie bioluminescente (BLI) de modèles in vivo.
ImageXpress Micro 4 –
Lumina III In Vivo Imaging System –
Envie d'en savoir plus ?
Neurodevelopmental disorder mouse models at InnoSer — TSC, Rett & STXBP1
in this month's update, we invite you to explore recent developments in rare neurodevelopmental disorders associated with epilepsy and seizure phenotypes. We highlight emerging therapeutic approaches, discuss the importance of selecting translationally relevant...
Your compound has shown efficacy in a preclinical disease model – now what? Moving from exploratory studies to GLP toxicology studies
A practical guide to transitioning from exploratory studies to GLP toxicology when outsourcing your non-clinical safety program to a specialist GLP toxicology CRO.Demonstrating efficacy in a disease model represents a major milestone in preclinical drug development....
Plasma NfL, p-tau217, or Aβ42/40: Which Alzheimer’s disease biomarkers should you include in your preclinical efficacy study?
A practical guide to preclinical Alzheimer’s disease biomarkers panel selection when you’re considering outsourcing to a specialist neurology CRO Biomarkers have transformed Alzheimer's disease clinical trials, enabling diagnosis confirmation for trial eligibility,...



